Citation 70304

RADISKY,DC: RADISKY,ES: BARROWS,LR: COPP,BR: KRAMER,RA: IRELAND,CM:. (1993). NOVEL CYTOTOXIC TOPOISOMERASE II INHIBITING PYRROLOIMINOQUINONES FROM FIJIAN SPONGES OF THE GENUS ZYZZYA.. 115(5)

Citation Details

Title	NOVEL CYTOTOXIC TOPOISOMERASE II INHIBITING PYRROLOIMINOQUINONES FROM FIJIAN SPONGES OF THE GENUS ZYZZYA.
Authors	RADISKY,DC: RADISKY,ES: BARROWS,LR: COPP,BR: KRAMER,RA: IRELAND,CM:
Year	1993
Volume	115
Issue	5

Summary

Year: 1993

Journal: Unknown

Organisms and Their Experiments (2)

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOANTICANCER AND/OR CYTOTOXICITY MARKER CODE	LEUROCRISTINE	INACTIVE
2	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOANTICANCER AND/OR CYTOTOXICITY MARKER CODE	LEUROCRISTINE	ACTIVE

Zyzzya marsailis (IOPHONIDAE)

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	Not specified	UV SPECTRUM GIVEN FORMASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE	MAKALUVAMINE A	None
2	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITROANTICANCER AND/OR CYTOTOXICITY MARKER CODE	MAKALUVAMINE A	ACTIVE
3	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITROANTICANCER AND/OR CYTOTOXICITY MARKER CODE	MAKALUVAMINE A	ACTIVE
4	TOPOISOMERASE II INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	MAKALUVAMINE A	ACTIVE
5	DNA NICKING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	MAKALUVAMINE A	ACTIVE
6	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOANTICANCER AND/OR CYTOTOXICITY MARKER CODE	MAKALUVAMINE A	INACTIVE
7	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOANTICANCER AND/OR CYTOTOXICITY MARKER CODE	MAKALUVAMINE A	INACTIVE
8	Not specified	UV SPECTRUM GIVEN FORMASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE	MAKALUVAMINE B	None
9	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITROANTICANCER AND/OR CYTOTOXICITY MARKER CODE	MAKALUVAMINE B	INACTIVE
10	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITROANTICANCER AND/OR CYTOTOXICITY MARKER CODE	MAKALUVAMINE B	WEAK ACTIVITY
11	TOPOISOMERASE II INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	MAKALUVAMINE B	INACTIVE
12	DNA NICKING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	MAKALUVAMINE B	WEAK ACTIVITY
13	Not specified	UV SPECTRUM GIVEN FORMASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE	MAKALUVAMINE B	None
14	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITROANTICANCER AND/OR CYTOTOXICITY MARKER CODE	MAKALUVAMINE B	WEAK ACTIVITY
15	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITROANTICANCER AND/OR CYTOTOXICITY MARKER CODE	MAKALUVAMINE B	WEAK ACTIVITY
16	TOPOISOMERASE II INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	MAKALUVAMINE B	WEAK ACTIVITY
17	DNA NICKING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	MAKALUVAMINE B	ACTIVE
18	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOANTICANCER AND/OR CYTOTOXICITY MARKER CODE	MAKALUVAMINE B	INACTIVE
19	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOANTICANCER AND/OR CYTOTOXICITY MARKER CODE	MAKALUVAMINE B	INACTIVE
20	Not specified	UV SPECTRUM GIVEN FORMASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE	MAKALUVAMINE D	None
21	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITROANTICANCER AND/OR CYTOTOXICITY MARKER CODE	MAKALUVAMINE D	WEAK ACTIVITY
22	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITROANTICANCER AND/OR CYTOTOXICITY MARKER CODE	MAKALUVAMINE D	WEAK ACTIVITY
23	TOPOISOMERASE II INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	MAKALUVAMINE D	WEAK ACTIVITY
24	DNA NICKING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	MAKALUVAMINE D	ACTIVE
25	Not specified	UV SPECTRUM GIVEN FORMASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE	MAKALUVAMINE E	None
26	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITROANTICANCER AND/OR CYTOTOXICITY MARKER CODE	MAKALUVAMINE E	ACTIVE
27	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITROANTICANCER AND/OR CYTOTOXICITY MARKER CODE	MAKALUVAMINE E	ACTIVE
28	TOPOISOMERASE II INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	MAKALUVAMINE E	WEAK ACTIVITY
29	DNA NICKING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	MAKALUVAMINE E	ACTIVE
30	Not specified	UV SPECTRUM GIVEN FORMASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE	MAKALUVAMINE F	None
31	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITROANTICANCER AND/OR CYTOTOXICITY MARKER CODE	MAKALUVAMINE F	ACTIVE
32	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITROANTICANCER AND/OR CYTOTOXICITY MARKER CODE	MAKALUVAMINE F	STRONG ACTIVITY
33	TOPOISOMERASE II INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	MAKALUVAMINE F	ACTIVE
34	DNA NICKING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	MAKALUVAMINE F	ACTIVE
35	Not specified	ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA	DISCORHABDIN A	None
36	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITROANTICANCER AND/OR CYTOTOXICITY MARKER CODE	DISCORHABDIN A	STRONG ACTIVITY
37	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITROANTICANCER AND/OR CYTOTOXICITY MARKER CODE	DISCORHABDIN A	STRONG ACTIVITY
38	TOPOISOMERASE II INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	DISCORHABDIN A	INACTIVE
39	DNA NICKING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	DISCORHABDIN A	ACTIVE
40	Not specified	UV SPECTRUM GIVEN FORISOLATION AND IDENTIFICATION OFMASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORQUANTITATIVE DATA	DAMIRONE B	None
41	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITROANTICANCER AND/OR CYTOTOXICITY MARKER CODE	DAMIRONE B	INACTIVE
42	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITROANTICANCER AND/OR CYTOTOXICITY MARKER CODE	DAMIRONE B	INACTIVE
43	TOPOISOMERASE II INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	DAMIRONE B	INACTIVE
44	DNA NICKING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	DAMIRONE B	INACTIVE
45	Not specified	UV SPECTRUM GIVEN FORISOLATION AND IDENTIFICATION OFMASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORQUANTITATIVE DATA	MAKALUVONE	None
46	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITROANTICANCER AND/OR CYTOTOXICITY MARKER CODE	MAKALUVONE	INACTIVE
47	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITROANTICANCER AND/OR CYTOTOXICITY MARKER CODE	MAKALUVONE	INACTIVE
48	TOPOISOMERASE II INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	MAKALUVONE	INACTIVE
49	DNA NICKING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	MAKALUVONE	INACTIVE